These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: A microcosting study of diagnostic tests for the detection of coronary artery disease in The Netherlands.
    Author: Tan SS, Oppe M, Zoet-Nugteren SK, Niezen RA, Kofflard MJ, Ten Cate FJ, Hakkaart-van Roijen L.
    Journal: Eur J Radiol; 2009 Oct; 72(1):98-103. PubMed ID: 18703301.
    Abstract:
    OBJECTIVE: The primary aim of the present study was to calculate the actual costs of four diagnostic tests for the detection of coronary artery disease in the Netherlands using a microcosting methodology. As a secondary objective, the cost effectiveness of eight diagnostic strategies was examined, using microcosting and reimbursement fees subsequently as the cost estimate. DESIGN: A multicenter, retrospective cost analysis from a hospital perspective. SETTING: The study was conducted in three general hospitals in the Netherlands for 2006. INTERVENTIONS: Exercise electrocardiography (exECG), stress echocardiography (sECHO), single-photon emission computed tomography (SPECT) and coronary angiography (CA). RESULTS: The actual costs of exECG, sECHO, SPECT and CA were 33, 216, 614 and 1300 euro respectively. For all diagnostic tests, labour and indirect cost components (overheads and capital) together accounted for over 75% of the total costs. Consumables played a relatively important role in SPECT (14%). Hotel and nutrition were only applicable to SPECT and CA. Diagnostic services were solely performed for CA, but their costs were negligible (2%). Using microcosting estimates, exECG-sECHO-SPECT-CA was the most and CA the least cost effective strategy (397 and 1302 euro per accurately diagnosed patient). Using reimbursement fees, exECG-sECHO-CA was most and SPECT-CA least cost effective (147 and 567 euro per accurately diagnosed patient). CONCLUSIONS: The use of microcosting estimates instead of reimbursement fees led to different conclusions regarding the relative cost effectiveness of alternative strategies.
    [Abstract] [Full Text] [Related] [New Search]